Skip to content
PICO Portalanswers from OpenAlex

Early Decline in Cancer Antigen 125 as a Surrogate for Progression-Free Survival in Recurrent Ovarian Cancer

PaperCitations, authors & open-access status

Early Decline in Cancer Antigen 125 as a Surrogate for Progression-Free Survival in Recurrent Ovarian Cancer is a paper indexed in PICO Portal from OpenAlex.

How many citations does Early Decline in Cancer Antigen 125 as a Surrogate for Progression-Free Survival in Recurrent Ovarian Cancer have?

PICO Portalcitation count

Early Decline in Cancer Antigen 125 as a Surrogate for Progression-Free Survival in Recurrent Ovarian Cancer has 50 citations in the OpenAlex counts PICO Portal stores.

When was Early Decline in Cancer Antigen 125 as a Surrogate for Progression-Free Survival in Recurrent Ovarian Cancer published?

PICO Portalyear

Early Decline in Cancer Antigen 125 as a Surrogate for Progression-Free Survival in Recurrent Ovarian Cancer has 2011 year in the PICO Portal index.

What is the open-access status of Early Decline in Cancer Antigen 125 as a Surrogate for Progression-Free Survival in Recurrent Ovarian Cancer?

PICO Portaloa status

Early Decline in Cancer Antigen 125 as a Surrogate for Progression-Free Survival in Recurrent Ovarian Cancer has closed oa status in the PICO Portal index.

What is the DOI of Early Decline in Cancer Antigen 125 as a Surrogate for Progression-Free Survival in Recurrent Ovarian Cancer?

PICO Portaldoi

The DOI for Early Decline in Cancer Antigen 125 as a Surrogate for Progression-Free Survival in Recurrent Ovarian Cancer is on the source record.

What is the PMID of Early Decline in Cancer Antigen 125 as a Surrogate for Progression-Free Survival in Recurrent Ovarian Cancer?

PICO Portalpmid

The PMID for Early Decline in Cancer Antigen 125 as a Surrogate for Progression-Free Survival in Recurrent Ovarian Cancer is on the source record.

What is the OpenAlex record for Early Decline in Cancer Antigen 125 as a Surrogate for Progression-Free Survival in Recurrent Ovarian Cancer?

PICO Portalopenalex

The OpenAlex for Early Decline in Cancer Antigen 125 as a Surrogate for Progression-Free Survival in Recurrent Ovarian Cancer is on the source record.

Related on PICO Portal

470M+ articles · 14-day free trial